Viz

The company's core offering, the Viz.ai One platform, uses a suite of FDA-cleared AI algorithms to analyze medical images like CT scans, EKGs, and echocardiograms in real-time. This enables the platform to automatically detect suspected diseases, such as strokes, pulmonary embolisms, aortic dissections, and aneurysms, and immediately alert the entire specialized care team via a HIPAA-compliant mobile application. This process dramatically reduces the time to diagnosis and intervention, streamlining communication and care pathways between hospitals and specialists.

Viz.ai operates on a subscription-based SaaS model, charging hospitals and health systems an annual fee. This model has proven successful, with the platform adopted by over 1,700 hospitals in the U.S. and Europe. The company also partners with pharmaceutical and medical device companies to help accelerate patient access to new therapies and support clinical trial recruitment. Having achieved a valuation of $1.2 billion in April 2022, Viz.ai has raised significant funding from investors including Tiger Global, Insight Partners, Kleiner Perkins, and GV (formerly Google Ventures).